PARP Inhibitors in Triple-Negative Breast Cancer including Those with BRCA Mutations

Keyphrases

• Triple-negative Breast Cancer 100%
• BRCA mutation 100%
• PARP Inhibitors (PARPi) 100%
• Breast Cancer 66%
• Clinical Practice 33%
• Patient Demographics 33%
• Metastatic Breast Cancer 33%
• Inhibitor Therapy 33%
• Poly(ADP-ribose) Polymerase 33%
• BRCA2 mutation 33%
• BRCAness 33%
• Base Excision Repair 33%
• Poly (ADP-ribose) Polymerase Inhibition 33%
• Cancer-associated 33%
• Germline 33%
• Homologous Recombination Deficiency 33%
• Single-strand DNA Breaks 33%
• Active Research 33%

Medicine and Dentistry

• Triple Negative Breast Cancer 100%
• PARP Inhibitor 100%
• BRCA Mutation 100%
• Breast Cancer 66%
• Poly ADP Ribose Polymerase 66%
• Germ Cell 33%
• Lethality 33%
• Patient Population 33%
• Metastatic Breast Cancer 33%
• BRCA2 33%
• BRCA1 33%
• Base Excision Repair 33%
• Homologous Recombination 33%
• Single-Strand DNA Break 33%